Real-world effectiveness and safety of bleomycin in patients with keloids and hypertrophic scars: a systematic review and meta-analysis
Archives of Dermatological Research · 2025
DOI: 10.1007/s00403-024-03687-6 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Archives of Dermatological Research, 2025. Verfasst von Qimeng Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Yanbian University Hospital, 1327 Juzi St, Yanji, 133002, Jilin, China. Hauptthemen laut MEDLINE: Bleomycin, Cicatrix, Hypertrophic, Keloid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of China.
Abstract (Originalsprache)
Pathological scars are classified into hypertrophic scars and keloids, and currently have poor treatment outcomes and high recurrence rates. Bleomycin has received widespread attention in scar treatment in recent years, but there is currently no exploration on its real-world data. PubMed, Embase, and Cochrane databases were searched, and eight retrospective studies on the use of bleomycin for treatment were included, covering a total of 562 patients with keloids and hypertrophic scars. The meta-analysis results revealed that 90% of patients had significant flattening of scars after treatment with bleomycin, 5% had moderate flattening, and 4% had mild flattening. The recurrence rate after treatment was only 3%. The major adverse reaction was hyperpigmentation, with an incidence rate of 8%, and no significant ulcers or skin atrophy were reported. Subgroup analysis showed that the significant flattening rate treated with bleomycin alone was 91%, which was significantly different from the 79% treated with bleomycin in combined with triamcinolone acetonide, but the difference was not statistically significant. In addition, the significant flattening rate was 99% in Western patients and 57% in Asian patients, reflecting the impact of racial differences on treatment outcomes. There was no statistically significant difference in curative effects between males and females (RR: 0.95; P = 0.77). Overall, bleomycin has good curative effect in treating scars and has high safety, especially showing more significant effects in Western populations. However, racial differences, treatment plans, and other factors may affect the therapeutic effect of bleomycin. Future research can further explore the mechanisms of these factors and provide more personalized treatment plans for patients with scar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Department, Yanbian University Hospital, 1327 Juzi St, Yanji, 133002, Jilin, China.
- Dermatology Department, Yanbian University Hospital, 1327 Juzi St, Yanji, 133002, Jilin, China. 184766436@qq.com.
- Dermatology Department, Yanbian University Hospital, 1327 Juzi St, Yanji, 133002, Jilin, China. jinzh_621@163.com.
Förderung
- Natural Science Foundation of China
Zitieren
APA
Wang, Q., Ren, Z., Jin, W., & Jin, Z. (2025). Real-world effectiveness and safety of bleomycin in patients with keloids and hypertrophic scars: a systematic review and meta-analysis. Archives of Dermatological Research. https://doi.org/10.1007/s00403-024-03687-6
Vancouver
Wang Q, Ren Z, Jin W, Jin Z. Real-world effectiveness and safety of bleomycin in patients with keloids and hypertrophic scars: a systematic review and meta-analysis. Archives of Dermatological Research. 2025. doi:10.1007/s00403-024-03687-6
BibTeX
@article{Wang2025,
author = {Wang, Qimeng and Ren, Zhesheng and Jin, Wenyu and Jin, Zhehu},
title = {Real-world effectiveness and safety of bleomycin in patients with keloids and hypertrophic scars: a systematic review and meta-analysis},
journal = {Archives of Dermatological Research},
year = {2025},
doi = {10.1007/s00403-024-03687-6}
}
EUVIMED